207 Poster Session 2 - Connective Tissue Oncology Society

Scientific Posters – Poster Session 2rhabdomyosarcoma (5.6, 75%), and pleomorphic sarcoma(6.0, 73%) had generally higher MCL1 expression.Conclusion: Sarcomas have low-MCL1 expressioncompared with non-mesenchymal malignancies such ascarcinomas and melanoma. Among sarcomas, synovialsarcoma, clear cell sarcoma, and chondrosarcoma seemto be the strongest candidates for navitoclax therapy becausethey have been both characterized in the literatureas expressing high BCL2, and shown to have low-MCL1expression in our study.versus 75.0% for patients with high and low sN-CAD levels(Fig. 2). The multivariate analysis demonstrated that thesN-CAD levels is an independent prognostic factor for thedisease-free survival (p=0.0146; 95% CI, 0.212-0.844).Conclusion: Our results indicate that sN-CAD is presentin significantly higher amounts in patients with malignantbone and soft tissue tumors than in healthy subjects. Inaddition, a high serum sN-CAD level is associated with apoor outcome in musculoskeletal tumor patients. sN-CADis therefore a potentially valuable pre-therapeutic factor forpredicting the long-term survival in patients.Poster #158SOLUBLE N-CADHERIN AS A BIOMARKER FORMALIGNANT BONE AND SOFT TISSUE TUMORSAkihiko Matsumine, MD, PhD; Rui Niimi; Takahiro Iino;Shigeto Nakazora; Tomoki Nakamura; Takao Matsubara;Kunihiro Asanuma; Atsumasa Uchida; Akihiro SudoDepartment of Orthopedic Surgery, Mie University GraduateSchool of Medicine, Tsu City, JapanObjective: Neural-cadherin(N-cadherin) is one of theimportant molecules involved in tissue morphogenesis,wound healing, and the maintenance of tissue integrity. Recently,the cleavage of N-cadherin by ADAM10 has becomea focus of attention in the field of cancer biology. The aimsof this study are to investigate the serum N-cadherin(sN-CAD) levels in patients with malignant bone and soft tissuetumors, and to evaluate the prognostic significance of thesN-CAD levels.Methods: We examined the level of serum soluble N-cadherin(sN-CAD) using an ELISA in 80 malignant bone andsoft tissue tumors (bone sarcoma, n=23; soft tissue sarcoma,n=51; metastatic bone cancer, n=6) and 87 normal controls.The mean age of the patients was 51 years (range, 10–85years) and the mean follow-up period was 45 months(range, 1-144 months). The immunoenzymometric assayfor the sN-CAD levels was performed using a home-madeELISA plate.Results: The median serum sN-CAD level was 1254 ng/ml(range, 135–2860 ng/ml) in the cancer patients. The levelsmeasured in the patients were higher than those found inthe controls, who had a median serum level of 108 ng/ml(range, 0–540 ng/ml; P